The deal with Biodesix is worth US$28mln over five years and will also see the two companies work together to develop further the EarlyCDT test in both the US and elsewhere.
Oncimmune signs exclusive distribution deal in US for its lung cancer test
Quick facts: Oncimmune
Price: 37.5 GBX
Market Cap: £23.72 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Oncimmune named herein, including the promotion by the Company of Oncimmune in any Content on the Site, the Company receives from said issuer...FOR OUR FULL DISCLAIMER CLICK HERE